Sepracor, Inc.

Other

The United States of America As Represented by the Secretary of

Georgetown University

The Mclean Hospital Corporation

James W Young

Timothy J Barberich

Nancy M Gray

Steven Brandt

A K Gunnar Aberg

William J Wechter

Martin H Teicher

Raymond L Woosley

A K Aberg

Yiwang Chen

Malcolm M Furniss

Methods and compositions are disclosed utilizing the optically pure (&minus;) isomer of amlodipine. This compound is a potent drug for the treatment of hypertension while avoiding the concomitant liability of adverse effects associated with the racemic mixture of amlodipine. The (&minus;) isomer of amlodipine is also useful for the treatment of angina and such other conditions as may be related to the activity of (&minus;) amlodipine as a calcium channel antagonist such as cerebral ischemia, cerebral disorders, arrhythmias, cardiac hypertrophy, coronary vasospasm, myocardial infarction, renal impairment and acute renal failure, without the concomitant liability of adverse effects associated with the racemic mixture of amlodipine.

Methods for treating hypertension, angina, and congestive heart failure using of optically pure (-) amlodipine

Methods and compositions are disclosed utilizing the optically pure (S)-isomer of lomefloxacin to treat bacterial infection. In particular, this compound is a potent drug for the treatment of Mycobacteria infection.

Methods and compositions for treating infection using optically pure (S)-lomefloxacin

Methods are disclosed utilizing the optically pure (&minus;)-isomer of bupropion, which is a potent drug for treating depression, Parkinson's disease, obesity, weight gain and other disorders.

Methods for treating depression and other disorders using optically pure (&minus;)-bupropion

Optically pure (&minus;) amlodipine compositions

Methods for treating hypertension and angina using salts of optically pure (&minus;) amplodipine

Methods and compositions are disclosed utilizing the optically pure (&plus;) isomer of zopiclone. This compound is a potent drug for the treatment of sleep disorders, such as insomnia, and convulsive disorders, such as epilepsy. Similarly, these novel compositions and methods are useful for the treatment of sleep disorders and convulsive disorders while avoiding the concomitant liability of adverse effects associated with the racemic mixture of zopiclone. The optically pure (&plus;) isomer of zopiclone is also useful for treating disorders that are affected by the binding of agonists to central nervous system or peripheral benzodiazepine receptors. Also described are methods and compositions for treating disorders that are affected by binding of agonists to central nervous system or peripheral benzodiazepine receptors while avoiding the adverse effects associated with the administration of the racemic mixture of zopiclone.

Methods and compositions for treating disorders, using optically pure (&plus;) zopiclone

Methods and compositions are disclosed utilizing the optically pure (&minus;)-isomer of bupropion, which is a potent drug for treating depression.

Method for treating depression using optically pure (&minus;)-bupropion

Methods are disclosed utilizing the optically pure (&minus;) isomer of amlodipine. This compound is a potent drug for the treatment of hypertension while avoiding the concomitant liability of adverse effects associated with the racemic mixture of amlodipine. The (&minus;) isomer of amlodipine is also useful for the treatment of angina and such other conditions as may be related to the activity of (&minus;) amlodipine as a calcium channel antagonist such as cerebral ischemia, cerebral disorders, arrhythmias, cardiac hypertrophy, coronary vasospasm, myocardial infarction, renal impairment and acute renal failure, without the concomitant liability of adverse effects associated with the racemic mixture of amlodipine.

Methods and compositions for treating conditions caused by excessive calcium influx in cells using optically pure (-) amlodipine

Methods and compositions are disclosed utilizing the optically pure (&minus;)-isomer of bupropion, which is a potent drug for treating, Parkinson's disease.

Methods for treating Parkinson's disease using optically pure (&minus;)-bupropion

Compositions for treating infection using optically pure (S)-lomefloxacin

Methods are disclosed utilizing the optically pure (-)-isomer of bupropion, which is a potent drug for treating obesity and weight gain.

Methods for treating obesity and weight gain using optically pure

The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with albuterol.

Method for treating bronchospasm using optically pure R(-) albuterol

Methods for treating infection using optically pure (S)-lomefloxacin

Methods are disclosed utilizing the optically pure (+) isomer of cisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of cisapride.

Growing community of inventors

Palo Alto, CA, United States of America

James W Young